术前卡铂/紫杉醇联合氟尿嘧啶（5-FU）放化疗治疗老年食管癌。
Pre-operative Carboplatin/Paclitaxel 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer.
机构信息
Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas City, KS, U.S.A.
Department of Medicine, Division of Hematology/Oncology, South Florida University/Moffit Cancer Center, Tampa, FL, U.S.A.
出版信息
Anticancer Res. 2022 Jan;42(1):59-66. doi: 10.21873/anticanres.15457.
BACKGROUND/AIM: This study aimed to compare the efficacy and tolerability of pre-operative platinum/5-fluorouracil (P5F) and carboplatin/paclitaxel (CP), in combination with radiation therapy in older adults with locally advanced, stage I-III esophageal cancer.
PATIENTS AND METHODS
We retrospectively reviewed 51 patients aged ≥70 years who underwent chemoradiotherapy followed by esophagectomy for stage I-III esophageal cancer between 2008 and 2018. Pathological complete response (pCR) and survival rates were compared across the two chemotherapy regimen arms.
RESULTS
Treatment completion (p=0.28), pCR (p=0.89), and partial response rates were similar across both chemotherapy groups. Overall survival (OS) and disease-free survival (DFS) were similar across both groups with HR=0.80 (p=0.62) and HR=0.72 (p=0.72) respectively.
CONCLUSION
The lesser toxic CP regimen may be used in older patients with locally advanced esophageal cancer, with tumor response and survival rates similar to P5F chemotherapy.
背景/目的：本研究旨在比较术前铂类/5-氟尿嘧啶（P5F）和卡铂/紫杉醇（CP）联合放化疗在局部晚期 I-III 期食管癌老年患者中的疗效和耐受性。
患者和方法
我们回顾性分析了 2008 年至 2018 年间接受放化疗后行食管癌切除术的 51 例年龄≥70 岁的患者。比较了两种化疗方案组的病理完全缓解（pCR）率和生存率。
结果
两组的治疗完成率（p=0.28）、pCR 率（p=0.89）和部分缓解率相似。两组的总生存（OS）和无病生存（DFS）率相似，HR 分别为 0.80（p=0.62）和 0.72（p=0.72）。
结论
对于局部晚期食管癌的老年患者，毒性较小的 CP 方案可能与 P5F 化疗具有相似的肿瘤反应率和生存率。
Zotero 插件